INVESTMENT OPPORTUNITY IN INNOVATIVE CARDIAC TREATMENT - EPIHEART SHARE ISSUE OPEN

EpiHeart Oy is a Finnish medtech company that enables Cardiac Micrograft Therapy™ treatment with proprietary medical devices. The treatment aims to stimulate cardiac tissue recovery and improve heart function in individuals with heart disease.

The company is seeking funding to take Cardiac Micrograft Therapy™ to wider clinical efficacy studies. EpiHeart is already at clinical phase, as the first clinical efficacy study ongoing in Finland is using company's devices in the study. 

EpiHeart is well positioned as a future leader in the field of cardiac cell therapy. Read more about the company and the opportunities from the Information Memorandum below and subscribe shares by contacting CEO Kai Kronström.